Sugi Predict

Sugi Predict / Compounds / SCHEMBL18474178

SCHEMBL18474178

SCHEMBL18474178

CCO/N=C(\N)N/N=C/c1ccncc1Cl

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ ALDH1A1 P00352 2/20 0.38
▸ LMNA P02545 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ NCOA3 Q9Y6Q9 1/20 0.36
▸ MAPT P10636 2/20 0.35
▸ MAPK1 P28482 2/20 0.35
▸ GRK2 P25098 2/20 0.34
▸ RXFP3 Q9NSD7 2/20 0.34
▸ RXFP4 Q8TDU9 1/20 0.34
▸ NPC1 O15118 3/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ L3MBTL1 Q9Y468 2/20 0.34
▸ USP2 O75604 1/20 0.34
▸ MCOLN3 Q8TDD5 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ KLF5 Q13887 1/20 0.34
▸ GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17402454 0.92 MEN1 (0.34) MEN1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL17402468 0.82 LMNA (0.49) MEN1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL18437980 0.82 LMNA (0.49) MEN1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL18888894 0.79 ALDH1A1 (0.37) MEN1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL17402464 0.79 ALDH1A1 (0.37) MEN1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL18888908 0.78 LMNA (0.45) MEN1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL15875058 0.77 KMT2A (0.39) MEN1KMT2ALMNASMN1; SMN2MAPT
SCHEMBL15875061 0.77 KMT2A (0.39) MEN1KMT2ALMNASMN1; SMN2MAPT
SCHEMBL17395780 0.76 LMNA (0.45) MEN1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL18474175 0.76 LMNA (0.45) MEN1KMT2AALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10675257-B2 Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent INFLECTIS BIOSCIENCE (FR) 2020-06-09 — — US disclosed
US-20180221310-A1 METHOD OF TREATING CANCER WITH A COMBINATION OF BENZYLIDENEGUANIDINE DERIVATIVES AND CHEMOTHERAPEUTIC AGENT INFLECTIS BIOSCIENCE (FR) 2018-08-09 — — US disclosed
US-20180221310-A1 METHOD OF TREATING CANCER WITH A COMBINATION OF BENZYLIDENEGUANIDINE DERIVATIVES AND CHEMOTHERAPEUTIC AGENT INFLECTIS BIOSCIENCE (FR) 2018-08-09 — — US disclosed
WO-2017021216-A1 METHOD OF TREATING CANCER WITH A COMBINATION OF BENZYLIDENEGUANIDINE DERIVATIVES AND CHEMOTHERAPEUTIC AGENT. INFLECTIS BIOSCIENCE (FR) 2017-02-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180221310-A1 METHOD OF TREATING CANCER WITH A COMBINATION OF BENZYLIDENEGUANIDINE DERIVATIVES AND CHEMOTHERAPEUTIC AGENT MGMT, GLI1, CA9 MEN1 221/4885KMT2A 810/4885ALDH1A1 148/4885
US-10675257-B2 Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent MGMT, GLI1, CA9 MEN1 221/4885KMT2A 810/4885ALDH1A1 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.